875542-02-2

Basic information

• Product Name: 2,4-Oxazolidinedione, 5-methyl-5-(3-methylphenyl)-, (5R)-
• CAS NO: 875542-02-2
• Molecular Formula: C11H11NO3
• Molecular Weight: 205.213
• Mol File: 875542-02-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,4-Oxazolidinedione, 5-methyl-5-(3-methylphenyl)-, (5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Oxazolidinedione, 5-methyl-5-(3-methylphenyl)-, (5R)-(875542-02-2)
• EPA Substance Registry System: 2,4-Oxazolidinedione, 5-methyl-5-(3-methylphenyl)-, (5R)-(875542-02-2)

Safety Data

• Hazardous Substances Data: 875542-02-2(Hazardous Substances Data)

Upstream product

• 877681-24-8 (2R)-2-hydroxy-2-(3-methylphenyl)propanoic acid methyl ester 
• 57-13-6 urea 
• 875542-01-1 (2R)-2-(3-methylphenyl)propane-1,2-diol 
• 877932-06-4 (2R)-2-hydroxy-2-(3-methylphenyl)propanoic acid 
• 1124-20-5 2-(3-methylphenyl)propene 
• 585-74-0 3-Methylacetophenone 

Downstream Products

• 877681-25-9 (5R)-5-methyl-5-(3-methylphenyl)-N-trityl-oxazolidine-2,4-dione 
• 875542-03-3 (5R)-5-(3-bromomethylphenyl)-5-methyl-N-trityl-oxazolidine-2,4-dione 

Relevant articles and documents

Benzimidazolones: A new class of selective peroxisome proliferator- activated receptor γ (PPARγ) modulators

A series of benzimidazolone carboxylic acids and oxazolidinediones were designed and synthesized in search of selective PPARγ modulators (SPPARγMs) as potential therapeutic agents for the treatment of type II diabetes mellitus (T2DM) with improved safety profiles relative to rosiglitazone and pioglitazone, the currently marketed PPARγ full agonist drugs. Structure-activity relationships of these potent and highly selective SPPARγMs were studied with a focus on their unique profiles as partial agonists or modulators. A variety of methods, such as X-ray crystallographic analysis, PPARγ transactivation coactivator profiling, gene expression profiling, and mutagenesis studies, were employed to reveal the differential interactions of these new analogues with PPARγ receptor in comparison to full agonists. In rodent models of T2DM, benzimidazolone analogues such as (5R)-5-(3-{[3-(5-methoxybenzisoxazol-3-yl)benzimidazol-1-yl]methyl}phenyl) -5-methylox-azolidinedione (51) demonstrated efficacy equivalent to that of rosiglitazone. Side effects, such as fluid retention and heart weight gain associated with PPARγ full agonists, were diminished with 51 in comparison to rosiglitazone based on studies in two independent animal models. (Figure presented)

BENZOUREAS HAVING ANTI-DIABETIC ACTIVITY

Benzourea compounds of Formula I having aryl-(CH2)x-oxazolidinedione or aryl-(CH2)x-thiazolidinedione substituents on one of the N atoms of the benzourea ring, wherein x is 0 or 1, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia and other symptoms such as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity, that are often associated with type 2 diabetes. I